Actinium Pharmaceuticals to Host Webinar on June 12th to Update on Pivotal Phase 3 SIERRA Clinical Trial for Iomab-B
31 mai 2017 07h30 HE
|
Actinium Pharmaceuticals
- Dr. Rajneesh Nath, a Principal Investigator and Director of the Bone Marrow Transplant and Acute Leukemia Program at Banner MD Anderson Cancer Center will discuss his perspectives on Iomab-B in...
Actinium Pharmaceuticals Granted Orphan Designation from the European Medicines Agency for Actimab-A
24 mai 2017 09h22 HE
|
Actinium Pharmaceuticals
- Orphan designation provides increased communication and guidance from regulators and 10-year market exclusivity upon marketing authorization- Actinium’s two leading drug candidates, Iomab-B and...
Actinium Pharmaceuticals to Present Actimab-A Data at the 10th International Symposium on Targeted Alpha Therapy
23 mai 2017 07h30 HE
|
Actinium Pharmaceuticals
- Data from the Company’s Actimab-A program to be presented in the Clinical Experiences session being held on Wednesday, May 31, 2017 - Actinium is a sponsor of the conference...
Actinium Pharmaceuticals Announces Appointment of Hematology Expert Dr. Richard Stone of the Dana-Farber Cancer Institute to its Scientific Advisory Board
17 mai 2017 07h00 HE
|
Actinium Pharmaceuticals
Dr. Stone is a world renowned physician with extensive research and clinical experience focused on refractory leukemia patients and advanced myeloproliferative disordersActinium’s Scientific Advisory...
Actinium Pharmaceuticals Receives Clearance from Health Canada to Initiate Pivotal Phase 3 SIERRA Trial of Iomab-B
10 mai 2017 07h00 HE
|
Actinium Pharmaceuticals
NEW YORK, May 10, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload...
Actinium Pharmaceuticals Announces Sponsorship of the Acute Leukemia Forum 2017
18 avr. 2017 07h00 HE
|
Actinium Pharmaceuticals
- Event to bring together worldwide experts to share and discuss latest research that is influencing treatment and management of patients with acute leukemia - Members of Actinium’s...
Actinium Pharmaceuticals Appoints Pharmaceutical Industry Executive Ajit S. Shetty, Ph.D., to the Company’s Board of Directors
28 mars 2017 07h00 HE
|
Actinium Pharmaceuticals
- Proven leader with 36 years of experience with Johnson & Johnson in numerous executive capacities, most recently as Head of Enterprise Supply Chain- Dr. Shetty was instrumental in establishing...
Actinium Announces Receipt of Positive Scientific Advice from the European Medicines Agency for Iomab-B
21 mars 2017 07h00 HE
|
Actinium Pharmaceuticals
- EMA guidance provides clear regulatory pathway for EU approval for Iomab-B - Trial design, primary endpoint and planned statistical analysis from the Iomab-B U.S. pivotal Phase 3 SIERRA trial...
Actinium Pharmaceuticals to Sponsor 4th Annual Summit on Hematologic Malignancies
16 mars 2017 17h30 HE
|
Actinium Pharmaceuticals
NEW YORK, March 16, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
Actinium Pharmaceuticals to Present at 29th Annual ROTH Conference
07 mars 2017 07h00 HE
|
Actinium Pharmaceuticals
NEW YORK, March 07, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...